Skip to main content
. Author manuscript; available in PMC: 2012 Apr 15.
Published in final edited form as: Clin Cancer Res. 2011 Feb 22;17(8):2328–2338. doi: 10.1158/1078-0432.CCR-10-2943

Figure 3.

Figure 3

VEGF121/rGel inhibited osteoblastic growth of MDA PCa 118b cells in bone. (A) Radiographic analysis of saline- and VEGF121/rGel–treated mice. Radiographs show right femurs 8 weeks after implantation of MDA PCa 118b cells. Arrows indicate the increased bone density in the saline-treated mice (left panels) and significantly lower bone density in the VEGF121/rGel–treated mice (right panels). (B) Representative microcomputed tomography (μCT) images reveal higher bone mass in the tumor-bearing femurs of saline-treated mice (left panels) than in the tumor-bearing femurs of VEGF121/rGel–treated mice (right panels). (C) Quantification of μCT data revealed that VEGF121/rGel normalized the bone volume fraction of 118b tumor-containing bone, as compared with the contralateral bone in the VEGF121/rGel-treated mice. (D) VEGF121/rGel treatment increased bone mineral density and reduced overall bone volume. (E) However, VEGF121/rGel treatment did not significantly affect overall bone mineral content.